AnaptysBio will discuss updated Phase 2b trial data for rosnilimab in rheumatoid arthritis on June 3, 2025.
Quiver AI Summary
AnaptysBio, Inc. announced they will host an investor call and live webcast on June 3, 2025, to share updated data from their Phase 2b RENOIR clinical trial, which is evaluating the investigational drug rosnilimab for moderate-to-severe rheumatoid arthritis. The call will feature Anaptys management and prominent rheumatology experts, including Dr. Paul Emery and Dr. Jonathan Graf. Following the data release, Anaptys executives, led by CEO Daniel Faga, will participate in several investor conferences, including the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. The live webcasts and subsequent replays will be accessible through the company's investor website. Anaptys is focused on developing innovative therapies for autoimmune diseases with rosnilimab at the forefront of their pipeline, alongside other candidates in various stages of clinical trials.
Potential Positives
- AnaptysBio is set to present updated data from the global Phase 2b RENOIR clinical trial, which could positively impact investor interest and confidence in the company's lead program, rosnilimab, for rheumatoid arthritis.
- The involvement of renowned experts, including Paul Emery, M.D., and Jonathan Graf, M.D., in the upcoming investor call adds credibility and interest to the significance of the clinical trial results.
- The company is actively participating in multiple investor conferences, showcasing its commitment to engaging with investors and enhancing visibility within the healthcare investment community.
Potential Negatives
- The press release focuses on a clinical trial (RENOIR) that is still in Phase 2b, indicating that the product rosnilimab is not yet approved, which may raise concerns regarding the viability and timeline of bringing this therapy to market.
- AnaptysBio is presenting data from a clinical trial, which may imply that previous data was not as favorable as expected, leading to the necessity for updates and further investor communications.
- The involvement of multiple investor conferences suggests the need for ongoing investor assurance, possibly indicating previous concerns regarding investor confidence or interest in the company's pipeline.
FAQ
What is the date of the investor call for AnaptysBio?
The investor call will take place on June 3, 2025, at 4:15pm ET / 1:15pm PT.
Who will present during the AnaptysBio investor call?
Anaptys management will be joined by Dr. Paul Emery and Dr. Jonathan Graf during the investor call.
Where can I watch the live webcast of the data release?
The live webcast will be available on the investor section of the Anaptys website.
What clinical trial data will AnaptysBio discuss?
AnaptysBio will review updated data from the Phase 2b RENOIR clinical trial of rosnilimab for rheumatoid arthritis.
What are AnaptysBio's key drug candidates?
AnaptysBio's lead program is rosnilimab, targeting PD-1+ T cells for rheumatoid arthritis and ulcerative colitis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ANAB Insider Trading Activity
$ANAB insiders have traded $ANAB stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ANAB stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 3 purchases buying 85,098 shares for an estimated $1,099,642 and 0 sales.
- HOLLINGS RENTON sold 10,000 shares for an estimated $250,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ANAB Hedge Fund Activity
We have seen 87 institutional investors add shares of $ANAB stock to their portfolio, and 103 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC added 3,764,720 shares (+433.3%) to their portfolio in Q1 2025, for an estimated $69,986,144
- POINT72 ASSET MANAGEMENT, L.P. added 2,368,370 shares (+inf%) to their portfolio in Q1 2025, for an estimated $44,027,998
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 1,816,466 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $33,768,102
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,573,719 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $29,255,436
- BANK OF AMERICA CORP /DE/ added 1,126,010 shares (+6273.4%) to their portfolio in Q1 2025, for an estimated $20,932,525
- FMR LLC removed 1,125,082 shares (-37.1%) from their portfolio in Q1 2025, for an estimated $20,915,274
- SOFINNOVA INVESTMENTS, INC. added 1,027,106 shares (+772.7%) to their portfolio in Q1 2025, for an estimated $19,093,900
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ANAB Analyst Ratings
Wall Street analysts have issued reports on $ANAB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 05/06/2025
- Wolfe Research issued a "Outperform" rating on 02/03/2025
To track analyst ratings and price targets for $ANAB, check out Quiver Quantitative's $ANAB forecast page.
$ANAB Price Targets
Multiple analysts have issued price targets for $ANAB recently. We have seen 3 analysts offer price targets for $ANAB in the last 6 months, with a median target of $25.0.
Here are some recent targets:
- Yatin Suneja from Guggenheim set a target price of $54.0 on 05/06/2025
- Andy Chen from Wolfe Research set a target price of $25.0 on 02/04/2025
- Emily Bodnar from H.C. Wainwright set a target price of $19.0 on 12/11/2024
Full Release
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT.
During the webcast, members of Anaptys management will be joined by Paul Emery, M.D., professor, Rheumatology, University of Leeds, Leeds Biomedical Research Centre, U.K. and Jonathan Graf, M.D., professor of Medicine, Rheumatology, University of California, San Francisco and a RENOIR clinical trial investigator.
Additionally, Anaptys president and chief executive officer, Daniel Faga, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences following the data release:
Jefferies Global Healthcare Conference, New York, NY
- Format – Presentation and one-on-one investor meetings
- Date and Time – Thursday, June 5, 2025, at 8:45am ET / 5:45am PT
Goldman Sachs 46 th Annual Global Healthcare Conference, Miami, FL
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, June 11, 2025, at 8:40am ET / 5:40am PT
Live webcasts of the data release, as well as the presentation and fireside chat, will be available on the investor section of the Anaptys website at
https://ir.anaptysbio.com/presentations-and-events
. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. The company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator, in Phase 1 trials. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (
Jemperli
(dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit
www.AnaptysBio.com
or follow us on
LinkedIn
.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
[email protected]
